focus -WSS

focus

author：knowledge 2025-10-04 04:00:43 - browse：85646

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The benefits and risks of Eli Lilly’s treatment for Alzheimer’s disease were confirmed in detailed scientific disclosures Monday, paving the way for its full approval but leaving physicians with lingering questions about the medicine’s impact on patients as a new era in Alzheimer’s therapy unfolds.

The drug, called donanemab, showed a 35% slowing of Alzheimer’s disease progression relative to placebo in a clinical trial that enrolled 1,700 patients with early-stage disease. Numerically, that’s a modest, 3.3-point improvement on a 144-point survey, called the Integrated Alzheimer’s Disease Rating Scale, or iADRS, that combines measures of cognition and function, such as driving, managing finances, or carrying on conversations.

There was a similar benefit when donanemab’s efficacy was assessed using a more common measure of cognition called the Clinical Dementia Rating-Sum of Boxes, or CDR-SB. On that scale, the Lilly drug showed a 36% slowing of cognitive decline relative to placebo, or 0.68 points on an 18-point scale.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： Organ aging and disease risk measured by new blood test

WSS

CDC director unscathed in first congressional testimony

Erich Jarvis studies song birds to learn about human stuttering

How to pay for weight loss drugs and save Medicare

How to pay for weight loss drugs and save Medicare

6 surprising facts about sugar

Surgeons perform first xenotransplant using CRISPR'd pig kidney

leisure time

focus

focus

How one medical school became remarkably diverse

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

This gene therapy has record $4.25 million price. It's saved children.

Affirmative action in medical school literally saved lives

Rep. Raul Ruiz on the physician shortage and more

Bright Health sells Medicare Advantage business to Molina

Medical devices makers are asking for forgiveness, not permission

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Organ aging and disease risk measured by new blood test

hotspot

Rep. Raul Ruiz on the physician shortage and more

Medical devices makers are asking for forgiveness, not permission

Readout Newsletter: Illumina, CRISPR, Regeneron

What Kate Middleton's cancer revelation might teach the world

This gene therapy has record $4.25 million price. It's saved children.

Despite FDA concern, risk that CAR

explore

focus

focus

explore